Universal reference book for medicines
Product name: KAGOCHEL ® (KAGOCEL ® )

Active substance: nonappropriate

Type: Antiviral and immunomodulating drug.
Interferon synthesis inducer
Manufacturer: НИАРМЕДИК ПЛЮС ООО (Russian Federation)
Composition, form of production and packaging
? Tablets from white with a brownish tinge to light brown color biconcave with a patch of brown.
1 tab.
kagocel 12 mg
Auxiliary substances: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) - to obtain a tablet weighing 100 mg.
10 pieces. - packings of cellular contour (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2017.
PHARMACHOLOGIC EFFECT
Antiviral drug, inducer of interferon synthesis. The active substance is the sodium salt of the copolymer (1> 4) -6-0-carboxymethyl-? -D-glucose, (1> 4) -? - D-glucose and (21> 24) -2,3,14,15 , 21,24,29,32-octahydroxy-23- (carboxymethoxymethyl) -7,10-dimethyl-4, 13-di (2-propyl) -19,22,26,30,31-pentaoxaheptacyclo [23.3.2.2 16.20 .0 5.28 .0 8.27 .0 9.18 .0 12.17 ] docriaconta-1,3,5 (28), 6,8 (27), 9 (18), 10,12 (17), 13,15-decene.
It causes the formation in the human body of so-called late interferons, which are a mixture of alpha and beta interferons, which have high antiviral activity. Kagocel induces the production of interferons in virtually all cell populations that participate in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When administered in a single dose of Kagocel®, the interferon titer in serum reaches its maximum values ​​after 48 h. The interferon response of the body to the administration of kagocella is characterized by a prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of accumulation of interferons in the intestine when taking the drug inside does not coincide with the dynamics of circulating interferon titers. In the blood serum, interferon production reaches high values ​​only 48 hours after the administration of kagocel, while in the intestine the maximum production of interferons is observed after 4 hours.
The drug Kagocel ® when prescribed in therapeutic doses is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, it is not carcinogenic and does not have an embryotoxic effect.
The greatest effectiveness in the treatment with Kagocel ® is achieved with its appointment no later than the 4th day after the onset of an acute infection. For preventive purposes, the drug can be used at any time, incl. and immediately after exposure to the infectious agent.
PHARMACOKINETICS
Suction and distribution
When administered orally, the total blood flow is about 20% of the administered dose of the drug. 24 hours after the introduction into the body, the drug accumulates mainly in the liver, to a lesser extent - in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentration is noted in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of kagocel in the brain is explained by the high molecular weight of the drug, which hinders its penetration through the BBB. In blood plasma the preparation is mainly in a bound form: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.
With daily repeated administration of Kagocella V d varies widely in all organs studied. The accumulation of the drug in the spleen and lymph nodes is especially pronounced.
Excretion
It is excreted from the body, mainly through the intestine: after 7 days after intake, 88% of the administered dose is withdrawn from the body, incl. 90% through the intestine and 10% by the kidneys. In the exhaled air the drug was not detected.
INDICATIONS
- prevention and treatment of influenza and other acute respiratory viral infections in adults and children aged 3 years;
- Treatment of herpes in adults.
DOSING MODE
The drug is taken orally, regardless of food intake.
Adults for treatment of influenza and SARS are prescribed in the first 2 days - 2 tab. 3 times / day, in the following 2 days - 1 tab. 3 times / day. In total, the course lasts 4 days - 18 tab.
Prevention of influenza and ARVI is carried out by 7-day cycles: 2 days - 2 tab. 1 time / day, break for 5 days. Then the cycle is repeated. The duration of the preventive course is from 1 week to several months.
For the treatment of herpes , 2 tablets are prescribed. 3 times / day for 5 days. In total for a course lasting 5 days - 30 tab.
Children aged 3 to 6 years for treatment of influenza and SARS are prescribed in the first 2 days - 1 tab. 2 times / day, in the next 2 days - 1 tab. 1 time / day. In total, the course lasts 4 days - 6 tab.
Children aged 6 years and older for treatment of influenza and SARS are prescribed in the first 2 days - 1 tab. 3 times / day, in the following 2 days - 1 tab. 2 times / day. In total for a course lasting 4 days - 10 tab.
In children aged 3 years and older, the prevention of influenza and ARVI is carried out by 7-day cycles: 2 days - 1 tab. 1 time / day, break for 5 days, then the cycle is repeated. The duration of the preventive course is from 1 week to several months.
SIDE EFFECT
Possible: allergic reactions.
If any of these side effects are aggravated, or the patient has noticed any other side effects, he should inform the doctor about it.
CONTRAINDICATIONS
- Pregnancy;
- the period of lactation (breastfeeding);
- children's age till 3 years;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
Due to the lack of necessary clinical data, the drug is not recommended for use during pregnancy and lactation (breastfeeding).
Impact on the ability to drive vehicles and manage mechanisms
The effect of the drug on the ability to drive vehicles and mechanisms has not been studied.
APPLICATION FOR CHILDREN
Contraindicated in children under 3 years

SPECIAL INSTRUCTIONS
To achieve a therapeutic effect, Kagocel ® should be taken no later than the 4th day after the onset of the disease.
Claims of consumers should be sent to the address: LLC "NEARMEDIC PLUS", Russia, 125252, Moscow, ul. 12 Mikoyan Aircraft Design Office, phone / fax: +7 (495) 385-80-08, e-mail: safety@nearmedic.ru
OVERDOSE
Treatment: In case of accidental overdose, it is recommended to prescribe an abundant drink, induce vomiting.
DRUG INTERACTION
Kagocel ® is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect).
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, protected from light at a temperature of no higher than 25 ° C. Shelf life - 4 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!